R2WA Stock Overview
Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 3/6 |
Past Performance | 3/6 |
Financial Health | 6/6 |
Dividends | 5/6 |
Beximco Pharmaceuticals Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ৳0.47 |
52 Week High | ৳0.53 |
52 Week Low | ৳0.37 |
Beta | 0.64 |
1 Month Change | 8.80% |
3 Month Change | 7.80% |
1 Year Change | 13.53% |
3 Year Change | -53.92% |
5 Year Change | 0.19% |
Change since IPO | 17.27% |
Recent News & Updates
Recent updates
Shareholder Returns
R2WA | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | 7.8% | 1.1% | 1.2% |
1Y | 13.5% | -23.8% | 5.5% |
Return vs Industry: R2WA exceeded the German Pharmaceuticals industry which returned -23.8% over the past year.
Return vs Market: R2WA exceeded the German Market which returned 5.5% over the past year.
Price Volatility
R2WA volatility | |
---|---|
R2WA Average Weekly Movement | 8.0% |
Pharmaceuticals Industry Average Movement | 6.2% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.0% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: R2WA has not had significant price volatility in the past 3 months.
Volatility Over Time: R2WA's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1976 | n/a | n/a | https://www.beximcopharma.com |
Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh. The company provides allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskeletal, oncology, respiratory, urogenital, skin care, vitamin and mineral supplement, and other products, as well as contract manufacturing services to other companies. It offers its products in various dosage forms, including solid, liquid, cream and ointment, suppositories, metered dose and dry powder inhaler, nasal spray, sterile, lyophilized injectable, and large volume intravenous fluids.
Beximco Pharmaceuticals Limited Fundamentals Summary
R2WA fundamental statistics | |
---|---|
Market cap | €441.08m |
Earnings (TTM) | €41.48m |
Revenue (TTM) | €351.38m |
10.6x
P/E Ratio1.3x
P/S RatioIs R2WA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
R2WA income statement (TTM) | |
---|---|
Revenue | ৳41.65b |
Cost of Revenue | ৳23.62b |
Gross Profit | ৳18.03b |
Other Expenses | ৳13.12b |
Earnings | ৳4.92b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 11.02 |
Gross Margin | 43.30% |
Net Profit Margin | 11.80% |
Debt/Equity Ratio | 14.5% |
How did R2WA perform over the long term?
See historical performance and comparison